Publisher
Springer International Publishing
Reference172 articles.
1. ClinicalTrials.gov. Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID19 Patients Trial (COVID-PACT). Identifier: NCT04409834. Last updated June 1, 2020. https://clinicaltrials.gov/ct2/show/NCT04409834.
2. Lurie N, Saville M, Hatchett R, Halton J. Developing CoViD19 Vaccines at Pandemic Speed. N Engl J Med. 2020;382(21):1969–73. https://doi.org/10.1056/NEJMp2005630.
3. Cao Bin et al. A trial of lopinavir–ritonavir in adults hospitalized with severe CoViD19. New England Journal of Medicine. 2020.
4. Horby Peter W et al. Lopinavir–ritonavir in patients admitted to hospital with COVID19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2020;396.10259 (2020):1345–52.
5. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–704. https://doi.org/10.1016/S0140-6736(20)31042-4.